{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:21:15Z","timestamp":1777364475866,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.medj.2025.100665","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T14:35:42Z","timestamp":1744382142000},"page":"100665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["AMPLIFY: A second-generation BTK inhibitor for fixed-duration therapy in chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2795-6507","authenticated-orcid":false,"given":"Stefano","family":"Molica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100665_bib1","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100665_bib2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/hematology.2024000656","article-title":"Risk-stratification in frontline CLL therapy: standard of care","volume":"2024","author":"Tausch","year":"2024","journal-title":"Hematology. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.medj.2025.100665_bib3","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2025.100665_bib4","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease","volume":"390","author":"Munir","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100665_bib5","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib\u2013venetoclax versus chlorambucil\u2013obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2025.100665_bib6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1200\/JCO.24.01192","article-title":"End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia","volume":"43","author":"Simon","year":"2025","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100665_bib7","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100665_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100034","article-title":"Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice","volume":"1","author":"Timofeeva","year":"2024","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.medj.2025.100665_bib9","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100665_bib10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025000923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025000923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T19:13:45Z","timestamp":1745003625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025000923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2666634025000923"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100665","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AMPLIFY: A second-generation BTK inhibitor for fixed-duration therapy in chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100665"}}